Project Grant R43AG060843

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

TAUTRACE: Ultrasensitive Immunoassay Platform for Alzheimer's Disease Biomarkers Adeptrix Corp received a $499,940 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective September 11, 2025, with a completion date of August 31, 2026. The company is developing TAUTRACE, an ultrasensitive immunoassay platform designed to detect and quantify phosphorylated tau (pTau) protein biomarkers in cerebrospinal fluid and plasma samples at...

This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....

The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...

Tiaki Therapeutics Inc. was awarded a $1,099,720 cooperative agreement from the National Institute on Aging, part of the National Institutes of Health within the Department of Health and Human Services, to support research under the Aging Research program (CFDA 93.866). The award will fund the optimization of Tiaki's lead small molecule compounds that modulate sphingosine 1-phosphate receptor signaling to treat Alzheimer's disease by reducing neuroinflammation. Specifically, the funding will...

The National Institute on Aging (NIA) awarded a $1,994,202 Project Grant under CFDA 93.866 - Aging Research to Mayo Clinic Jacksonville (A Nonprofit Corporation) to research a new microglial therapy candidate for Alzheimer's disease (AD) that could prevent cognitive decline. The grant aims to target the tumor susceptibility gene 101 (TSG101) in microglia to manipulate extracellular vesicle secretion and mitigate tau pathology development. The research will be conducted in three phases: targeting...

Federal Project Grant Summary The National Institute on Aging (NIA) awarded a $9.78 million Project Grant to the Institute for Molecular Medicine Inc. under the Aging Research program (CFDA 93.866) to conduct a multicenter Phase 1 clinical trial evaluating the safety and immunogenicity of AV-1980R/A, a preventive tau vaccine candidate for Alzheimer's disease (AD). The trial, operating under FDA-approved Investigational New Drug (IND) Application 29644, will enroll cognitively unimpaired...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is supporting the evaluation of the safety, tolerability, and immunogenicity of an adjuvanted preventive dual AB/Tau vaccine, DUVAX, in healthy volunteers. The $499,754 award to Nuravax, Inc. will fund a Phase 1 study to investigate this novel Alzheimer's disease (AD) vaccine candidate that aims to inhibit both amyloid-beta (AB) and pathological tau aggregation,...